Arx @JoinArx

$ENTX Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds Read the Full News Release 👉 globenewswire.com/news-release/2…

$NVCT Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights Read the Full Press Release 👉 globenewswire.com/news-release/2…

$PYPD Q4 Investor Call is happening today. What a year it has been and more is coming. See our PR to learn more about timing of FDA submission, new branding and new technology platform: investors.polypid.com/news-releases/…

$ENTX We’re pleased to see Entera Bio featured in Citeline Pink Sheet’s coverage of the FDA’s qualification of total hip bone mineral density as a validated surrogate endpoint for osteoporosis drug development. insights.citeline.com/pink-sheet/pat… (Authored by Sue Sutter)

$NSRX Nasus Pharma Announces Pricing of $15.0 Million Private Placement Read the full press release here: globenewswire.com/news-release/2…

$NSRX Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder Read the full press release here: globenewswire.com/news-release/2…

What historical data shows about market activity the day after MLK day. Read @yehudaleibler's latest deep dive.

Yehuda Leibler @yehudaleibler

5 months ago

x.com/i/article/2013…

3 2 8 22K 7

Congratulations to Duke Robotics (OTCQB: DUKR) which recently announced a $750,000 Private Placement at a Premium to Market The Company intends to use the net proceeds from the private placement for working capital, and general corporate purposes, including supporting ongoing operational and commercialization initiatives the Company is pursuing. Duke Robotics develops advanced stabilization and autonomous robotic drone systems for both civilian and defense markets. The Company’s Insulator Cleaning Drone (IC Drone) is a first-of-its-kind, drone-enabled system for cleaning and monitoring high-voltage electric utility insulators. Leveraging Duke’s technologies, the IC Drone provides a safer, more efficient, and cost-effective alternative method. In defense, through a collaboration agreement with Elbit the Bird of Prey weapons drone system is an agile, fully stabilized remote weapon system designed for non-line-of-sight and stand-off engagements, marketed by Elbit under the brand name Bird of Prey Read more: lnkd.in/dSCNBxwi

Today is the time the Tel Aviv Stock Exchange (@TASE_IL) will be open on a Sunday. Staring 2026, it will shift to trading Monday-Friday, instead of Sunday-Thursday, as one of the measures to make it more attractive and aligned for the international investment community.

Is the Santa Clause Rally Real? yehudaleibler.substack.com/p/is-the-santa…

Yehuda Leibler @yehudaleibler

6 months ago

I analyzed 22 years of stock market data over the holidays. The Santa Claus Rally isn't a myth. It's a 72.7% win rate. The setup is simple: last 5 trading days of December, first 2 of January. Seven days total. Since 2003, the S&P 500 has been positive in 16 of 22 years,

0 1 7 2K 2

$NSRX Citizens analyst Jason N. Butler has initiated coverage of Nasus with a Market Outperform rating and a $19 price target.

@finnishcp KOL event is live on Stocktwits right now - stocktwits.com/symbol/PYPD/co… - IR Team

Arx was pleased to support Silexion Therapeutics in its efforts to maintain its Nasdaq listing. After raising $6M, completing a reverse split and navigating the nasdaq hearing processes, Silexion has recently announced that it has regained compliance with Nasdaq's minimum bid and shareholders equity requirements. Read more: globenewswire.com/news-release/2…

$NSRX - Laidlaw analyst Yale Jen has initiated coverage of Nasus with a Buy rating and a $22 12-month price target. This reflects Laidlaw’s analysis as of the date of the report and is not an endorsement of it

Congratulations to our client DarioHealth, on their recent announcement of new financing of $17.5M via a private placement priced at-the-market under nasdaq rules. DarioHealth is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. The company's ai powered platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health. Read more: prnewswire.com/news-releases/…

Arx founders @yehudaleibler and @rotemgantz were featured in this year’s Business Leaders Special by Yedioth Ahronoth - an annual magazine spotlighting Israel’s top business leaders, published in honor of the Jewish New Year (Rosh Hashana). In an exclusive interview, they shared how Arx is becoming the “operating system” for publicly traded companies - helping them gain true observabity into their stock while optimizing and streamlining their investor relations. 📈✨ We’re proud to see our founders’ vision and the dedication of the entire Arx team recognized in such an influential publication as we head into another year of growth and innovation. ynet.co.il/economy/rememb…

Should publicly traded companies in the US be allowed to report earnings just twice a year, instead of quarterly? In an article for @Investingcom I wrote about this not-so-new debate which @realDonaldTrump just reignited: investing.com/analysis/from-… Other markets have already tested it - from the UK and EU to Israel and Japan. The outcome have been mixed: reduced compliance burdens for some issuers, but also thinner analyst coverage, more volatility, and little evidence of greater long-term investment. This is not a one-size-fits-all question. For early-stage, R&D focused cash-burning firms, lighter updates could free focus and resources. For large-caps and index constituents, steady quarterly detail remains essential for trust, comparability, and liquidity. Exchanges and institutional investors can also play a role in setting disclosure standards, as Germany’s tiered approach has shown. Markets thrive on trust, and trust thrives on information. The SEC’s challenge is not whether to abandon quarterlies altogether, but how to recalibrate them - scaling back where the burden is greatest, while preserving transparency where the stakes are highest.

What happens when a single Trump post questions the entire U.S. quarterly reporting system? @YehudaLeibler breaks down why this debate matters, what other markets have tried, and how the SEC could rewrite the rules of disclosure. Could semiannual reporting really save costs - or just leave investors flying blind? Read the full column on @Investingcom: investing.com/analysis/from-…